Acromegaly, a rare endocrine disorder, results in excessive secretion of pituitary growth hormone (GH) in the bloodstream. The symptoms of Acromegaly appear so slow, that by the time it is diagnosed, health problems such as associated cardiovascular, cerebrovascular, and respiratory disorders and malignancies begin to develop. Acromegaly is treatable. The Acromegaly treatment market comprises surgery, medications, and radiation therapy. However, not all therapies are effective for all the Acromegaly patients.
Several pharma companies are developing novel therapies to advance the Acromegaly pipeline and address the treatment challenges. Some of the key companies in the Acromegaly market includes Antisense Therapeutics, Aquestive Therapeutics, ASCIL PROYECTOS, Auritec Pharmaceuticals, Camurus Chiasma, Crinetics Pharmaceuticals, Dauntless Pharmaceuticals, Enesi Pharma Limited, FORESEE PHARMACEUTICALS, Ionis Pharmaceuticals, Rani Therapeutics, and many others.
For more details visit:
https://www.delveinsight.com/blog/acromegaly-pipeline/